

program



the
**extracellular
matrix**
pharmacology
congress

*Fresh ideas,
bright science,
next-generation therapies*

the 3rd extracellular matrix
pharmacology congress 2026

14-17 JUNE 2026
COPENHAGEN
DENMARK

Index

Organisation	5
Welcome to ECM2026	7
General Information	8
Social Events	9
About ISECMP	10
Speakers at ECM2026	11
Program	15
Poster Overview	27
Floor Plan	34
Sponsor & Exhibitor Directory	35
Media Partners	41
Thank you to our sponsors and exhibitors	48





Organisation

Scientific Committee

Adam Platt	Emna Ouni	Manu Chakravarthy
Alexander Eckersley	Florian Rieder	Morten A. Karsdal
Alexandra Møller	Fredrik Sundberg	Nikos Karamanos
Alexandra Naba	Gianluca Matteoli	Ole Kaasbøll
Andrea Heinz	Gisli Jenkins	Philipp E. Scherer
Bram Verstockt	Joachim Lehmann	Raghu Kalluri
Cecilie Bager	John Varga	Roberta Martinelli
Christian Vestergaard	Kevin Hart	Saurabh Gupta
Dana Orange	Kevin S. Wei	Scott Friedman
Detlef Schuppan	Kjetil Ask	Stephane Heymans
Dinesh Khanna	Lykke Hinsch Gylvin	Thomas Cox
Don Lynn Gibbons	Mads Bastrup Israelsen	Thomas H. Barker
Douglas Maya-Miles	Maja Thiele	



Welcome to ECM2026

Dear colleagues,

We are pleased to welcome you to ECM2026.

Hosted by the International Society of Extracellular Matrix Pharmacology (ISECMP), ECM2026 brings together the extracellular matrix (ECM) community in Copenhagen for four days of science, discussion, and collaboration.

We meet at a time of significant progress in ECM research. In recent years, the field has moved from basic biological insights to therapeutic innovation. We now see the first ECM-targeted therapies reaching patients – with antifibrotic treatments emerging in liver fibrosis, and additional therapies in late development for lung fibrosis. This marks a transition from concept to clinic – one that we are proud to celebrate together.

The progress is driven by a growing recognition of the role of fibroblasts and ECM dynamics across organs. Fibrogenesis is involved in approximately 40% of deaths in the Western world - yet remains underrepresented in current therapeutic strategies. ECM2026 provides a platform to address this gap. Identifying both common and organ-specific mechanisms of fibrosis, including the interplay between fibro-inflammation and systemic, multi-organ disease, will be essential. It is clear that meaningful innovation can only be achieved through collaboration across disciplines, institutions, and sectors.

Collaboration and innovation are at the core of ECM2026, and our slogan - Fresh ideas, bright science, next-generation therapies - captures both this ambition and the translational potential of our field. Building on the success of the two previous biennial ECM congresses, including ECM2024, which brought together 450+ participants and featured 180 abstracts and 80 oral presentations, ECM2026 marks the third congress in this series and stands as a testament to the continued growth and strength of our community. We look forward to continuing this momentum together.

Thank you for being part of ECM2026.

Sincerely,



Morten A. Karsdal
PhD, Professor
Chair ECM2026

General Information

Congress Website

www.ecm-congress.org

Congress Venue

Tivoli Hotel & Congress Center
Arni Magnussons Gade 2
DK-1577 Copenhagen

Hosted by



The International Society of Extracellular Matrix Pharmacology

Vesterlundvej 20
DK-2730 Herlev
info@isecmp.org
www.isecmp.org

Congress Secretariat



CAP Partner
Nordre Fasanvej 113
DK-2000 Frederiksberg
Tel.: +45 70 20 03 05
info@cap-partner.eu
www.cap-partner.eu

Badges

Please wear your congress badge at all times. Access to the venue requires a valid badge issued by the congress secretariat.

Information for Speakers

Please bring your presentation on a USB stick to the **Speakers Preview Room** at the congress venue. A technician will assist you with uploading the presentation. Please ensure that your presentation is uploaded at least 2 hours before your session starts. Presentations should be prepared in 16:9 format using Microsoft PowerPoint. *Personal laptops cannot be used for presentations.* Presentations will be deleted after the congress to ensure copyright compliance.

Speakers Preview Room

Opening hours:

Sunday, 14 June	Closed*
Monday, 15 June	07:00 - 18:30
Tuesday, 16 June	07:00 - 18:00
Wednesday, 17 June	07:00 - 12:30

*) Closed, but it is possible to upload slides online. Please ask in the registration or visit the congress website.

Registration opening hours

Opening hours:

Sunday, 14 June	13:00 - 19:00
Monday, 15 June	07:00 - 18:45
Tuesday, 16 June	07:30 - 17:50
Wednesday, 17 June	08:00 - 12:45

Wi-Fi

Free Wi-Fi is provided at the venue.

Network Name:

Tivoli Hotel & Congress Center

Password: tivolihotel

Social Events

Welcome Reception

Date 14 June 2026
Time 17:30 - 19:00
Place Exhibition Area

Join us as we celebrate that the first ECM-targeted therapies are now reaching patients.

The reception is included in the registration.

Congress Dinner

Date 16 June 2026
Time 18:00 - 24:00
Place Langelinie Pavillonen

Transportation:

Boat transfer to Langelinie Pavillonen is included in the congress dinner ticket. Return transportation after the event is not included. Public transportation is available within walking distance, including Østerport Station (10–15 minutes' walk) and Marmorkirken Metro Station (approximately 15 minutes' walk).


- Boats will depart from the harbour directly across from the congress venue.
- Please meet at the registration at 17:55, where staff will guide you to the harbour.
- The first boat (capacity: 100 guests) departs at 18:00, followed by another boat 10 minutes later.

NB: The congress dinner is not included in the registration.

Morning Fun Run

Date 16 June 2026
Time 08:00 - 08:45
Place Meeting point: Registration

Join the 5 km run in the Copenhagen harbour area. Shower facilities are available at the congress venue for participants who are not staying at the congress hotel.



About ISECMP

The International Society of Extracellular Matrix Pharmacology (ISECMP) is an international non-profit scientific society dedicated to advancing basic, translational, clinical, and pharmacological research on the extracellular matrix. Founded in 2023, ISECMP brings together researchers, healthcare professionals, and industry experts working across matrix biology and pharmacology.

The society provides a multidisciplinary platform that promotes scientific exchange, international collaboration, education, and innovation in extracellular matrix research. Through congresses, webinars, and collaborative activities, ISECMP aims to advance the understanding of extracellular matrix mechanisms in health and disease while supporting the development of novel therapeutic strategies.

ISECMP is committed to fostering scientific excellence, supporting early-career researchers, and strengthening global collaboration within the extracellular matrix research community.



The International Society of Extracellular Matrix Pharmacology

Vesterlundvej 20
DK-2730 Herlev, Denmark

info@isecmp.org
www.isecmp.org

Speakers at ECM2026

Get an overview of the speakers at ECM2026




Aisyah Sjöholm
Associate Director
Insilico Medicine



Detlef Schuppan
Professor
University Medical Center
Mainz



Alexander Eckersley
Lecturer
University of Manchester




Dinesh Khanna
Professor
University of Michigan



**Alexander Lynge
Reese-Petersen**
Principal Scientist
Novo Nordisk




Don L. Gibbons
Professor
MD Anderson Cancer
Center



Alexandra Naba
Associate Professor
University of Illinois
Chicago



Florian Rieder
Professor
Cleveland Clinic



Andrea Heinz
Associate Professor
University of Copenhagen



Gisli Jenkins
Professor
Imperial College London



Bram Verstockt
Assistant Professor
KU Leuven



Giuseppe Mazza
Co-Founder and CEO
Engitix



Christian Vestergaard
Professor
Aarhus University



Guillaume Wettstein
Head of Translational
Science
Inventiva Pharma



Dana Orange
Associate Professor
Rockefeller University



Hamid Khoja
Chief Scientific Officer
FibroBiologics

Speakers at ECM2026

Get an overview of the speakers at ECM2026



Henrik H. Hansen
Scientific Director
Gubra A/S



Lisa Boyette
Executive Director
Eli Lilly




James K. Hennen
Vice President
Madrigal Pharmaceuticals




Lise Lotte Gluud
Professor
Copenhagen University
Hospital



Jeremy Garcia
Research Scientist
Xylyx Bio



Lykke Hinsch Gylvn
Chief Medical Officer
Boehringer Ingelheim



John Varga
Professor
University of Michigan




Mads Almose Røpke
Scientific Director
Novo Nordisk



Kevin Wei
Assistant Professor
Harvard Medical School



Mads Bastrup Israelsen
Associate Professor
University of Southern
Denmark



Lara Campana
SVP and Co-Founder
Resolution Therapeutics



Maja Sofie Thiele
Professor
University of Southern
Denmark



Lars Johansson
Chief Scientific Officer
Antaros




Manu Chakravarthy
Senior Vice President
Roche-Genentech



Lee Borthwick
CEO
FibroFind



Massimiliano Berardi
Product Manager
Optics11 Life



Mathieu M. Petitjean
Chief Engineering Officer
PharmaNest



Michael Clupper
Research Investigator
Incyte



Michael Eberhardson
Senior Medical Director
AstraZeneca



Morten A. Karsdal
CEO
Nordic Bioscience




Nicholas Willumsen
Director
Nordic Bioscience



Ole J. Kaasbøll
Co-Founder and CSO
Tribune Therapeutics



Philipp E. Scherer
Professor
UT Southwestern Medical
Center



Raghu Kalluri
Professor
MD Anderson Cancer
Center



Saurabh Gupta
Senior Director
Bristol Myers Squibb



Scott Friedman
Professor
Icahn School of Medicine at
Mount Sinai



Stephane Heymans
Professor
Maastricht University



Thomas H. Barker
Professor
University of Virginia



Thomas R. Cox
Professor
Garvan Institute of Medical
Research



Tina Vilsbøll
Senior Medical Officer
Novo Nordisk



Veronica Miller
Adjunct Professor
UC Berkeley School of
Public Health



Zoltan Derdak
Medical Director
Takeda



13:00 - 15:00	Registration	
15:00 - 16:00	Break-out industry session: Fibrosis models from ex vivo systems to animal models Chair: John Varga <i>Location: Harlekin</i>	Break-out industry session: Next-generation drug discovery in fibrosis and cancer Chair: Daniel Hargbøl Madsen <i>Location: Columbine</i>
	15:00 - 15:20 Get the full picture with quantitative 3D whole-organ imaging Henrik H. Hansen, Gubra A/S	15:00 - 15:20 Fibrosis in IBD: an evolving unmet need Michael Eberhardson, AstraZeneca
	15:20 - 15:40 Human precision-cut tissue slices as a preclinical platform for the development & testing of novel therapeutics Lee Borthwick, FibroFind	15:20 - 15:40 Extracellular matrix biomarkers as determinants of response and resistance in solid tumors Saurabh Gupta, Bristol Myers Squibb
	15:40 - 16:00 BigH3 in fibrosis and cancer Nicholas Willumsen, Nordic Bioscience	15:40 - 16:00 CSF-1R inhibition shows efficacy in multiple preclinical fibrosis models Michael Clupper, Incyte
16:15 - 17:30	Opening session <i>Location: Congress hall</i> Chairs: Morten A. Karsdal and Detlef Schuppan	
	16:15 - 16:30 Chair's welcome and introduction Morten A. Karsdal, Nordic Bioscience	
	16:30 - 17:30 Plenary keynote Celebrating the era of antifibrotics Maja Thiele, University of Southern Denmark	
17:30 - 19:00	Welcome reception Drinks, food and celebration <i>Location: Foyer</i>	Poster session A <i>Location: Congress hall (rear section)</i> Poster tours at 18:00 (meeting point: Registration) Categories: • Matrix biology and disease mechanisms • Matrix models and therapeutic innovation • Tumor microenvironment and ECM-targeted cancer therapies

Program

Monday, 15 June 2026

08:00 - 08:45	Break-out industry session: Imaging the dynamics of organ fibrosis Chair: Alexander Eckersley <i>Location: Pjerrot</i>	Speed networking Chair: Rune Vestermark <i>Location: Harlekin</i>
	08:00 - 08:20 Fibrogenesis imaging in man with novel PET-PDGF probes enabling real-time fibrosis activity assessment Lars Johansson, Antaros	
	08:20 - 08:40 Fibrotypes as dynamic systems: imaging and classifying ECM remodeling at single-fiber resolution Mathieu M. Petitjean, PharmaNest	
09:00 - 10:30	Plenary session: Intestines and the ECM: a target to treat? Chairs: Anne-Christine Bay-Jensen and Dana Orange	<i>Location: Congress hall</i>
	09:00 - 09:25 From mechanisms to medicines in stricturing Crohn's disease Florian Rieder, Cleveland Clinic	
	09:25 - 09:50 Beyond inflammation: the extracellular matrix in IBD: from signal to strategy Bram Verstockt, University Hospitals Leuven	
	09:50 - 10:00 Endotrophin-derived PRO-C6 identifies a fibrotic phenotype in Crohn's Disease Anja Poulsen, Rigshospitalet, University of Copenhagen	
	10:00 - 10:10 Inflammatory myeloid-stromal crosstalk drives pathogenic fibroblast activation in fibrostenotic Crohn's Disease Gianluca Matteoli, KU Leuven	
	10:10 - 10:20 Obefazimod shows evidence of dual anti-inflammatory and anti-fibrotic activity in murine in vivo and human in vitro models Julien Santo, Abivax	
10:30 - 11:00	Coffee break and exhibition	
11:00 - 12:30	Plenary session: Fibroblasts vs cancer cells – who is in control? Chairs: Janine Erler and Lars Henning Engelholm	<i>Location: Congress hall</i>
	11:00 - 11:25 It's not who's in control... It's what they're building that matters: The matrix as a determinant of tumour progression and therapy response Thomas R. Cox, Garvan Institute of Medical Research	
	11:25 - 11:50 Tumor-directed reprogramming of the microenvironment drives metastasis and treatment resistance in non-small cell lung cancer Don L. Gibbons, The University of Texas MD Anderson Cancer Center	
	11:50 - 12:00 TAX2 targets the TSP-1/CD47 matrix checkpoint to restore CD8* antitumor immunity and advances to first-in-human evaluation Aur�lie Moniot, Apmonia Therapeutics	
	12:00 - 12:10 CRTAC1 mediated changes in the ECM stiffness of Glioblastoma multiforme Devansh Swadia, Indian Institute of Science Education And Research Mohali	
	12:10 - 12:20 Bispecific decoys transform the melanoma microenvironment and sensitize tumors to immunotherapy Nikos Afratis, University of Athens	
12:30 - 13:15	Lunch and exhibition	

13:15 - 14:15	Break-out industry session: Strategies for fibrosis resolution Chair: Dinesh Khanna <i>Location: Columbine</i>	Break-out session: Degradomics and proteomics Chair: Fredrik Sundberg <i>Location: Harlekin</i>	Panel discussion: Young investigators, biotech/pharma career paths & entrepreneurship <i>Location: Pjerrot</i>
13:15 - 13:35	Regenerative macrophage therapy: Targeting chronic inflammation and fibrosis with a multimodal approach Lara Campana, Resolution Therapeutics	13:15 - 13:40 A unified proteomic framework for discovering extracellular matrix damage mechanisms Alexander Eckersley, University of Manchester	Panel: Lykke Hinsch Gylvin (Boehringer Ingelheim), Mads Bastrup Israelsen (Odense University Hospital), Morten A. Karsdal (Nordic Bioscience)
13:35 - 13:55	Targeting CCN proteins: Navigating the balance between antifibrotic efficacy and clinical tolerability Ole Kaasbøll, Tribune Therapeutics	13:40 - 13:45 Advancing sustained intra-articular delivery of antisense oligonucleotides through biomata: targeting inflammation and matrix degradation in osteoarthritis Ditte Elisabeth Jæhger, Hazel Therapeutics	
13:55 - 14:15	Lanifibranor a pan-PPAR agonist in MASH: Vascular and fibrotic remodeling Guillaume Wettstein, Inventiva Pharma	13:45 - 13:50 Lab-grown, 3D ECM particles accelerate wound healing, alter the proteome, and reduce fibrosis in aged mice Max Petersen, XM Therapeutics	
		13:50 - 13:55 ECM architecture is governed by BACE2-mediated collagen proteostasis Francesco Farris, IFOM ETS	
		13:55 - 14:00 Spatial and structural proteomics of photoageing human skin reveals damage across the dermal-epidermal basement membrane network Tess Birtles, University of Manchester	
		14:00 - 14:15 Q&A	

14:30 - 16:00	Plenary session: Tissue destruction in autoimmunity and chronic inflammation Chairs: Tim Welting and Tazio Maleitzke 14:30 - 14:55 Synovial stromal cells and joint pain Dana Orange, Rockefeller University 14:55 - 15:20 Pathogenic fibroblasts in refractory rheumatoid arthritis Kevin Wei, Harvard Medical School 15:20 - 15:30 TREM-1 promotes the progression and rupture of Marfan aortopathy Luna Chetrit, Université Paris Cité, Inserm, PARCC 15:30 - 15:40 High-fat and high-fat-sugar diets induce synovial fibrosis in Wistar-Han rats Ali Mobasheri, University of Oulu 15:40 - 15:50 Combining biomarkers of macrophage and fibroblast activity enhances prognostic performance in idiopathic pulmonary fibrosis Bilal M El-Masri, Nordic Bioscience			<i>Location: Congress hall</i>
16:00 - 16:30	Coffee break and exhibition			
16:30 - 17:30	Break-out industry session: From ECM biology to fibroblast-based therapies Chair: Scott Friedman <i>Location: Pjerrot</i>	Break-out industry session: ECM biomarkers, Reasonably Likely Surrogate Endpoints (RLSE), and regulatory considerations Chair: Maja Thiele <i>Location: Columbine</i>	Break-out session: Lightning late-breaking presentations Chair: Ali Mobasheri <i>Location: Harlekin</i>	
	16:30 - 16:50 A pan-matrisome tissue atlas of fibrosis and solid tumors to decode ECM composition and biology Giuseppe Mazza, Engitix Therapeutics	16:30 - 17:10 Current trends on liver fibrosis assessment: Moving beyond the biopsy Lise Lotte Gluud, Amager and Hvidovre Hospital, University of Copenhagen	16:30 - 16:35 Fibrosis activity vs disease stage: Complementary and independent predictors of outcomes in alcohol-related liver disease Stine Johansen, Odense Liver Research Center	
	16:50 - 17:30 Therapeutic potential of fibroblasts for the treatment of chronic diseases Hamid Khoja, FibroBiologics	17:10 - 17:30 Surrogate endpoints: Addressing challenges in complex chronic diseases Veronica Miller, UC Berkeley	16:35 - 16:40 LiverPRO can optimize trial recruitment and lower screen failure rates in steatotic liver disease Julie Astono, Evidio Health	
			16:40 - 16:45 3D human in vitro models to strengthen drug discovery in subretinal fibrosis Kathryn Rosowski, F. Hoffmann-La Roche Ltd.	

		16:45 - 16:50 Beyond inflammation: Investigating pro-fibrotic responses in human intestinal tissue slices from patients with or without Crohn's disease ex vivo Christina Hesse, Fraunhofer Item
		16:50 - 16:55 Tumor hypoxia stimulates the synthesis of an immunosuppressive extracellular matrix Daniel Hargbøl Madsen, Copenhagen University Hospital
		16:55 - 17:00 Limited Resilience of Visceral Adipose Tissue Following Weight Loss Reveals a Collagen Degradation Defect Geneviève Marcelin, Sorbonne Université
		17:00 - 17:05 Macrophages regulate collagen deposition through modulation of fibroblast circadian rhythms Joan Chang, University Of Manchester
		17:05 - 17:10 ECM biomarkers for evaluation of adverse event risk following radical prostatectomy Martin Rasmussen, Nordic Bioscience
		17:10 - 17:30 Q&A

17:40 - 18:40	Break-out session: Drug discovery and development - Lightning presentations Chair: Ditte Jæhger <i>Location: Columbine</i>	Break-out session: Extracellular matrix remodeling and fibrotic mechanisms - Lightning presentations Chair: Janine Erler <i>Location: Harlekin</i>
17:45 - 17:50	Leveraging copper targeting to remodel the tumour microenvironment in pancreatic cancer Ellie Mok, Garvan Institute of Medical Research	17:45 - 17:50 A novel preclinical mouse model to investigate mixed inflammatory phenotypes and mucus hyperproduction in COPD Silvia Siragusa, Chiesi Farmaceutici S.p.A
17:50 - 17:55	CD31+ Cell Enrichment Enhances Therapeutic Effects of Stromal Vascular Fraction in Experimental Primary Osteoarthritis Tazio Maleitzke, University of Copenhagen	17:50 - 17:55 To eat or not to eat: Degradation and engulfment capacities of macrophages in the context of pulmonary fibrosis Franziska Herrmann, Boehringer Ingelheim Pharma GmbH & Co. KG
17:55 - 18:00	Differential Therapeutic Profile of the Long-acting FGF21 analogue Efruxifermin in the GAN DIO-MASH and CDAA-HFD Mouse Models of MASH Monika Lewinska, Gubra A/S	17:55 - 18:00 NOTCH pathway inhibition by nirogacestat attenuates fibrotic processes in primary fibroblasts from patients with systemic sclerosis and localized scleroderma Valentina D'Agostino, Bambino Gesù Children's Hospital, IRCCS
18:00 - 18:05	Role of Angiotensin II inhibitors and scleraxis in treating cardiac fibrosis Sikta Chattopadhyaya, University of Manitoba	18:00 - 18:05 Examining ECM-regulated dormancy through p27kip1 reporter Mille Ravn, Biotech Research And Innovation Centre
18:05 - 18:10	JAK2 inhibition with ruxolitinib improves liver fibrosis Yingjie Ai, Johannes Gutenberg University Mainz	18:05 - 18:10 Endotrophin and CD44-mediated heterotypic signaling mediates tumor-stroma crosstalk and facilitates malignant progression in hepatocellular carcinoma Jiyoung Park, UNIST
18:10 - 18:15	LRP1 regulates extracellular S100A4 and links ECM signaling to target-mediated drug disposition Signe Vedel Borchert, Calluna Pharma	18:10 - 18:15 Macrophages are key regulators of extracellular matrix that promote fibrogenesis and maintain the fibrotic niche after injury cessation Kevin Hart, Pfizer
18:15 - 18:20	Clinical effect of oral blarcamersine on ECM in early Alzheimer's disease: Results of the Phase IIb/III trial Wolfgang Liedtke, Anavex Life Science	18:15 - 18:20 Liver Regeneration Triggers a Biphasic Matrisome Program Following Acute Hepatocyte Injury Enrica Wedig, Ludwig-Maximilians-Universität München
18:20 - 18:25	A broadly accessible alternative to monoclonal antibody therapy for fibroinflammatory diseases – A capsid virus-like particle-based vaccine displaying full-length interleukin-11 Louise Goksøyr, Adaptvac	18:20 - 18:25 Site- and stage specific chronic inflammation and fibrosis in Fuchs Endothelial Corneal Dystrophy Marion Fros, University Hospital Cologne, University of Cologne
18:25 - 18:40	Q&A	18:25 - 18:40 Q&A

08:00 - 08:45	Fun Run <i>Meeting point: Registration</i>	
08:00 - 08:45	Break-out industry session: 3D disease models: integrating matrix biology and mechanics Chair: Alexandra Naba <i>Location: Harlekin</i>	Break-out industry session: Rethinking fibrosis: biology, therapies, and AI Chair: Florian Rieder <i>Location: Pjerrot</i>
	08:00 - 08:20 IN MATRICO®: Advancing predictive, physiologically relevant disease modeling with tissue-specific dECM Jeremy Garcia, Xylyx Bio	08:00 - 08:20 Precision fibrogenesis in MASH: Finding the right patient for the right antifibrogenic therapy Zoltan Derdak, Takeda
	08:20 - 08:40 Mechanical cues as functional biomarkers of 3D in vitro models Massimiliano Berardi, Optics11 Life	08:20 - 08:40 Pharmaceutical superintelligence: How generative AI is reshaping ECM-targeting discovery for fibrosis, oncology, and inflammatory disease Aisyah Sjöholm, Insilico Medicine
09:00 - 10:30	Plenary session: <i>Location: Congress hall</i> Dermatology – a sign of a systemic disease Chairs: Gisli Jenkins and Stephane Heymans	
	09:00 - 09:25 Insights into ECM remodeling in skin aging and disease Andrea Heinz, University of Copenhagen	
	09:25 - 09:50 Beyond the barrier: collagen remodeling as a biomarker of skin inflammation in atopic dermatitis Christian Vestergaard, Aarhus University Hospital	
	09:50 - 10:00 Pan lysyl oxidase inhibitors dual targeting of collagen cross linking and growth factor receptor oxidation in skin scars and myelofibrosis Lara Perryman, Syntara	
	10:00 - 10:10 Characterization of skin calcium deposition, calcinosis cutis, in systemic sclerosis and dermatomyositis using ex vivo μCT imaging Laura Agerley Rørsgaard, Aarhus University Hospital	
	10:10 - 10:20 Spatially resolved proteomics reveals age- and menopause-associated extracellular matrix remodelling across dermal layers Gulsev Ozorun, The University of Manchester	
10:30 - 11:00	Coffee break and exhibition	

11:00 - 12:30	Plenary session: Drivers of multi-organ fibrosis Chairs: Mette Mogensen and John Varga	<i>Location: Congress hall</i>
	11:00 - 11:25 Breaking down the matrix: The interplay between fibrosis, inflammation, and autoimmunity in systemic sclerosis Dinesh Khanna, University of Michigan	
	11:25 - 11:50 "It's the matrix, stupid": Remodeling the ECM to impact weight loss quality and multimorbidity Manu Chakravarthy, Roche-Genentech	
	11:50 - 12:00 Measures of Fibrogenesis: Interpreting PRO-C3 and ELF in the MASH Response to Resmetirom, a Liver Directed Therapy James K. Hennen, Madrigal Pharmaceuticals	
	12:00 - 12:10 Hyaluronic acid and emergent extracellular matrix properties orchestrate mammalian regeneration Kevin Chalut, Cyclana Bio	
	12:10 - 12:20 Preclinical and phase I clinical development of MTX-474: A novel anti-ephrinB2 monoclonal antibody for the treatment of systemic sclerosis Allie M. Roach, Mediar Therapeutics	
12:30 - 14:00	Lunch, posters and exhibition	
	13:00 - 14:00 Poster Session B	<i>Location: Congress hall (rear section)</i>
	13:15 - 13:45 Poster Tours	<i>Meeting point: Registration</i>
	Categories: • Cardiovascular diseases and matrix remodeling • Liver fibrosis, MASH and precision medicine • Lung fibrosis and translational pulmonary models • Late-breaking abstracts	

14:00 - 15:00	Break-out industry session: Weight loss quality Chair: Manu Chakravarthy <i>Location: Columbine</i>	Break-out session: Endotrophin: When the matrix becomes a signal Chair: Detlef Schuppan <i>Location: Pjerrot</i>	Break-out session: Fibroblast heterogeneity and ECM remodeling in chronic disease Chair: Thomas Cox <i>Location: Harlekin</i>
	14:00 - 14:20 Weight loss, MASH, and the ECM Lisa Boyette, Eli Lilly	14:00 - 14:25 When fat gets stuck: Lipid droplets, fibrosis, and the metabolic fallout of obesity Philipp Scherer, UT Southwestern Medical Center	14:00 - 14:25 The functional contribution of type I collagen and type IV collagen in organ fibrosis and chronic diseases Raghu Kalluri, The University of Texas MD Anderson Cancer Center
	14:20 - 14:30 GLP-1 agonists from bench to bed Tina Vilsbøll, Novo Nordisk	14:25 - 14:35 Obesity-induced endotrophin accelerates endometrial cancer progression via WNT signaling pathway in an ER dependent manner Sahee Kim, UNIST	14:25 - 14:30 Cell-type resolved spatial proteomics reveals macrophage and fibroblast plasticity during liver fibrosis regression and progression Shani Ben-Moshe, Max Planck Institute for Biochemistry
	14:30 - 14:40 Effect of GLP-1 agonism on ECM modulation in MASH Mads Almose Røpke, Novo Nordisk	14:35 - 14:45 Preclinical efficacy and phase 1 safety and tolerability of VS-041: A novel MMP inhibitor for the treatment of HFpEF Noreen R. Henig, Vasa Therapeutics	14:30 - 14:35 Natural Asp-tRNA synthetase fragment interacts with LTBP-1 on the ECM promoting myofibroblast apoptosis and reducing fibrosis Ying-Ting Wang, aTyr Pharma, Inc.
	14:40 - 14:50 Effect of GLP-1 agonism on ECM modulation in CKD Alexander Lynge Reese-Petersen, Novo Nordisk	14:45 - 14:55 Endotrophin as a biomarker of biological aging Federica Genovese, Nordic Bioscience	14:35 - 14:40 Epigenetic reprogramming of stromal-epithelial crosstalk to improve immunotherapy response in pancreatic ductal adenocarcinoma Celia Martin-Otal, Barts Cancer Institute
	14:50 - 15:00 Q&A		14:40 - 14:45 INO313, a novel small molecule that reverses fibroblast activation and suppresses fibrotic remodeling Anastasia Mpakali, Biomedical Sciences Research Center "Alexander Fleming"
			14:45 - 15:00 Q&A

Program

Tuesday, 16 June 2026

15:00 - 16:30	Plenary session: <i>Location: Congress hall</i> The epithelium as a barrier in lung fibrosis and cardiovascular disease Chairs: Saher B. Shaker and Thomas Barker 15:00 - 15:25 Immune driven fibrosis in heart failure Stephane Heymans, Maastricht University 15:25 - 15:50 Scar Trek: When basal cells get beyond the barrier Gisli Jenkins, Imperial College London 15:50 - 16:00 RC-0315 Secretome: A multi-targeted regenerative approach for extracellular matrix remodelling in idiopathic pulmonary fibrosis Tali Fishman Jacob, Remedy Cell Ltd. 16:00 - 16:10 The insulin-like growth factor (IGF) axis is a potential regulator of ECM remodelling in carotid artery atherosclerosis Sara M. Jørgensen, University of Copenhagen 16:10 - 16:20 Serum biomarkers of collagen turnover and basement membrane repair in idiopathic pulmonary fibrosis: Evidence from the GRI-0621-IPF-02 phase 2a trial Marc Hertz, GRI Bio, Inc.
16:30 - 16:50	Coffee break and exhibition
16:50 - 17:30	Plenary Keynote <i>Location: Congress hall</i> Chairs: Detlef Schuppan and Henning Grønbaek Cellular therapeutics in fibrosis: Progress and prospects Scott Friedman, Icahn School of Medicine at Mount Sinai
17:55 - 24:00	Congress Dinner <i>Meeting point: Registration</i> (Separate ticket needed)

08:30 - 09:30	Plenary session: ECM-immune crosstalk and tissue remodeling Chairs: Henning Grønbæk and Mads Bastrup Israelsen 08:30 - 08:50 Immune cell – ECM interaction in fibrosis and cancer Detlef Schuppan, University Medical Center Mainz 08:50 - 09:00 Biopsy response and non-invasive biomarker improvements with survodutide: concordance analysis of phase 2 trial in metabolic dysfunction-associated steatohepatitis and fibrosis Renée Marshall, Boehringer Ingelheim Pharmaceuticals 09:00 - 09:10 Non-invasive biomarker improvements with survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis Renée Marshall, Boehringer Ingelheim Pharmaceuticals 09:10 - 09:20 Targeting the extracellular matrix in the tumour microenvironment with a novel antibody-drug conjugate Giuseppe Mazza, Engitix Therapeutics	Location: Congress hall
09:30 - 10:00	Coffee break	
10:00 - 11:30	Plenary session: ECM in health and disease Chairs: Don L. Gibbons & Dinesh Khanna 10:00 - 10:25 Leveraging mechanobiology to drug the fibrotic matrix Tom Barker, University of Virginia 10:25 - 10:50 Metabolic and epigenetic control of fibroblast memory in systemic sclerosis John Varga, University of Michigan 10:50 - 10:55 Monitoring the dynamics of the human skin ECM during aging Sarah Girardeau-Hubert, L'Oréal 10:55 - 11:00 Biomarkers of neutrophil and macrophage activity discriminate non-IBD from Crohn's disease and associate with endoscopic disease activity Marta Alexdóttir, Nordic Bioscience 11:00 - 11:05 Identifying key therapeutic biomarkers in pulmonary fibrosis: unraveling nintedanib's mechanisms in fibrotic human lung tissue slices Christina Hesse, Fraunhofer ITEM 11:05 - 11:10 Early efficacy biomarkers for treatments of liver fibrosis in MASH Anja Krüger, TNO 11:10 - 11:15 Circulating extracellular matrix remodelling trajectories in the general population Mehmet Nizamoglu, University Medical Center Groningen 11:15 - 11:30 Q&A	Location: Congress hall
11:30 - 12:30	Close of congress 11:30 - 11:45 Award ceremony Morten A. Karsdal, Nordic Bioscience 11:45 - 12:30 Plenary Keynote Chairs: Morten A. Karsdal and Andrea Heinz The matrisome project: from proteomic exploration of the extracellular matrix to matritherapies Alexandra Naba, University of Illinois Chicago	Location: Congress hall

ECM2028

11-14 June 2028 · Copenhagen · Denmark

Save
the date
ECM2028



Poster Overview

Nr.	Abstract Title	Presenter Author
P001	Structural characterization of a novel protein–peptide interface targeting a pro-fibrotic ECM regulator	Enrique Brandan, Universidad San Sebastian
P002	Serum thrombospondin 2 and a TSP2 based scoring system (SPHERE) predict fibrosis severity and clinical outcomes in AIH and PBC	Rambabu Surabattula, University Medical Center Mainz
P003	Extracellular matrix-biomarkers (C3M, PRO-C4, & ARGS) associate with pain profiles in knee osteoarthritis patients: Findings from the IMI-APPROACH study	Joscha Rombach, Nordic Bioscience
P004	Circulating levels of type I and type II procollagen propeptides, PRO-C1 and PRO-C2, reflect pubertal growth spurt in healthy adolescents	Yi He, Nordic Bioscience
P005	Tracing fibrogenesis with PRO-C3: A collagen III biomarker responsive to TGF- β inhibition in the Bleomycin Lung Fibrosis Model	Fabio Bignami, Chiesi Farmaceutici
P006	Serum C3C predicts survival in advanced PDAC and reflects TME protease activity relevant for ADC therapies	Marina Crespo Bravo, Nordic Bioscience
P007	Cellular activity biomarkers reflect Ocrelizumab response in patients with multiple sclerosis	Anna San Torcuato, Nordic Bioscience
P008	Dynamic changes in type III collagen formation and degradation are associated with fibrotic activity following hepatic injury in rats	Thomas Wiggers, Nordic Bioscience
P009	Biomarkers of blood-brain barrier turnover are increased in patients with Multiple Sclerosis	Meryem Benmarce, Nordic Bioscience
P010	Towards improved trial precision: Aligning drug mode of action with molecular endotypes	Monica T. Hannani, Nordic Bioscience
P011	Synovial-fluid extracellular vesicle proteomics reveals ECM remodelling signatures after intra-articular gold microparticle therapy in knee osteoarthritis	Sebastian L. Andree, Aalborg University
P012	Digital pathology and multi-omic profiling in abstinent patients with alcohol-related decompensated cirrhosis shows significant fibrosis regression associated with clinical improvement	Lisa Longato, Engitix Therapeutics
P013	VICM, a biomarker of macrophage-driven inflammation, as a risk marker of kidney disease progression in people with type 2 diabetes	Alexandra Møller, Nordic Bioscience
P014	Tumor fibrosis in plain sight: Why PRO-C3 deserves a place in oncology prognostication and trial design	Nicholas Willumsen, Nordic Bioscience
P015	Serial measurements of circulating extracellular matrix biomarkers in alcohol-related liver disease predict clinical outcomes	Ellen Lyngbeck Jensen, Odense University Hospital
P016	Mechanical cues as functional markers in 3D in vitro models	Massimiliano Berardi, Optics11 Life
P017	Synovial extracellular vesicles uncover ECM-remodelling biomarker signatures after intra-articular microgold therapy in knee osteoarthritis	Allan Stensballe, Aalborg University
P018	Psychophysiological changes induced by different volume of resistance exercise in major depressive disorder	Jessenia Marise Sales Campos, São Paulo State University
P019	ECM biomarkers for evaluation of erectile dysfunction following radical prostatectomy	Henning Nielsen, Zealand University Hospital
P020	Tumor-derived collagen I as an ECM driver of mesenchymal transformation and astrocyte reprogramming in glioblastoma	Andrea Comba, University Of Alabama At Birmingham
P021	Histotype-dependent collagen turnover in tumor-associated fibroblasts from NSCLC patients: defining new biomarkers and therapeutic targets	Victoria Batto, Universitat De Barcelona

Nr.	Abstract Title	Presenter Author
P022	Pulsed priming enhances chemotherapeutic efficacy in pancreatic cancer	Kendelle Murphy, Garvan Institute Of Medical Research
P023	Collagen prolyl 4-hydroxylases as therapeutic targets in pancreatic ductal adenocarcinoma	Sotiria Tsiflidou, University Of Oulu
P024	Full-length recombinant laminins support primary cells in vitro, by mimicking the natural niche for adult stem cells and cancer cells	Malin Kele, BioLamina
P025	Biomarkers for fibrosis and T-cell engagement in biliary tract cancer treated with nivolumab ± ipilimumab combined with SBRT (CheckPAC)	Martin Birkmose Rasmussen, Nordic Bioscience
P026	The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy	Martin Birkmose Rasmussen, Nordic Bioscience
P027	AdipoRon reduction of the invasive behavior of prostate cancer is related to the distinct EMT phenotype	Nicoletta Gagliano, University of Milan
P028	Post-translational modifications of extracellular matrix collagens differentially affect LAIR1 function	Rowie Borst, UMC Utrecht
P029	Tumor-associated fibroblast-dependent immunosuppression in NSCLC and its potential reversion with the antifibrotic drug Nintedanib	Jordi Alcaraz, Universitat De Barcelona
P030	Single-cell transcriptomic profiling of hepatocellular carcinoma development (HCC) in metabolic dysfunction-associated steatohepatitis (MASH)	Emma Rørbeck, Gubra
P031	Patients with myeloproliferative neoplasms exhibit elevated levels of the tumor-associated fibroblast biomarker PRO-C6	Caroline Norup Bistrup, Nordic Bioscience
P032	Serological detection of type XVII collagen shedding suggests prognostic relevance in Esophageal adenocarcinoma	Eleonora Moroncini, Nordic Bioscience
P033	Unlocking the extracellular matrix as a source of novel targets: a matrisome-based platform to characterize the tumour microenvironment	Emma Huang, Engitix Therapeutics
P034	Type III collagen formation and FAP-mediated type III collagen remodeling are independent predictors of poor outcome for patients with PDAC	Rasmus S. Pedersen, Nordic Bioscience
P035	Translating cancer-associated fibroblast (CAF) biology into clinically actionable biomarkers	Nicholas Willumsen, Nordic Bioscience
P036	Serum ECM biomarkers reveal dynamic stromal remodeling during neoadjuvant therapy in esophageal adenocarcinoma	Eleonora Moroncini, Nordic Bioscience
P037	Critical metabolic pathway regulates essential ECM genes driving metastatic seeding	Kasper Mygind, University of Copenhagen
P038	Differential fibronectin fibrillogenesis in the Glioblastoma niche hold the key for future tumor specific treatment strategies	Alexandra Bondaz, University of Geneva
P039	Dissecting the role of Basigin (CD147) in extracellular matrix secretion	Jéssica Roque, University of Copenhagen
P040	Interplay between hMENA and Lysyl Oxidase in regulating extracellular matrix properties and immune cell functions in Non-Small Cell Lung Cancer	Lorenzo Valenti, Regina Elena National Cancer Institute
P041	Proteomic characterisation of the uveal melanoma liver metastases extracellular matrix: conservations from the primary site and histopathological growth pattern differences.	Joshua Hattersley, University of Liverpool
P042	Characterisation of the bidirectional crosstalk between uveal melanoma and hepatic stellate cells	Karen Aughton, University of Liverpool
P043	TissueSpec® bone, liver, and lung dECM hydrogels for modeling organotropic breast cancer metastasis	Jeremy Garcia, Xylyx Bio
P044	Translating tumour extracellular matrix architecture into microfluidic platforms via high-resolution 3D microprinting for immunotherapy infiltration screening	Valeria Gonzalez Abrego, UCL

Nr.	Abstract Title	Presenter Author
P045	Deciphering the involvement of cancer associated fibroblasts on the aberrant vasculature in ccRCC and the resistance to targeted treatments	Victoire Rousseau, Inserm
P046	Chemoresistance-associated extracellular matrix remodelling in oesophageal adenocarcinoma cells	Giulia Costella, Nordic Bioscience
P047	Multiscale characterisation of stromal ECM remodelling in pancreatic cancer models	Kristen Burgess, University of Cambridge
P048	Molecular flexibility of high molecular weight hyaluronic acid has a profound effect on invasion of cancer cells	Agne Kuraite, University of Cambridge
P049	Recurrence of atrial fibrillation is reflected by elevated formation of collagen type III and VI after ablation therapy	Theodora Chrysoulidou, Nordic Bioscience
P050	Naturally occurring COL1 fragments induce COL3 formation in 3D PEG hydrogel model with human ventricular cardiac fibroblasts (HCF-v)	Tricia Sia Kjær, Roskilde University
P051	Modeling MYBPC3-driven hypertrophic cardiomyopathy using human 3D engineered heart tissues	Hamed Ghazizadeh, Curi Bio
P052	Extracellular matrix remodeling along the renal-cardiac axis in adenine-induced chronic kidney disease	Yalei Zang, Charité - Universitätsmedizin Berlin
P053	Potential of DYRK2 and AMPk as new chemotherapeutic targets against heart fibrosis induced by Chagas disease	Claudia Calvet, Fiocruz
P054	3D Artery-on-chip model: Study of matrix and flow disruption in the context of atherosclerosis	Lorraine Couteau-brisset, Novo Nordisk
P055	Precision mechanotherapies for treating cardiovascular fibrosis	Sangkyun Cho, Johns Hopkins University
P056	Cardiac fibrosis in aged rats	Andre Broermann, Boehringer Ingelheim
P057	Development of an ECM-based identification and validation platform for the discovery of novel therapeutic targets for liver fibrosis	Lisa Longato, Engitix Therapeutics
P058	3D light sheet microscopy unveils regional heterogeneity of myocardial fibrosis and response to GLP-1RA therapy	Sheyla Barrado Ballesterio, Gubra
P059	Endothelial cell-derived extracellular matrix dysregulation and impaired angiogenesis in 3D models of dilated cardiomyopathy	Lilla Jázmin Bakos, Semmelweis University
P060	Multiscale characterisation of extracellular matrix remodelling in LMNA-related dilated cardiomyopathy	Barbara Orsolits, Semmelweis University
P061	Development of a mechanically active immunocompetent organ-on-chip model of cardiac fibrosis	Sergi Gomez, BiomimX
P062	Circulating endotrophin is prognostic for incident heart failure in the general population	Clara F. G. Laursen, Nordic Bioscience
P063	Circulating endotrophin is associated with increased risk of mortality in individuals with HFrEF following hospital discharge for decompensated heart failure	Elisavet Angeli, Nordic Bioscience
P064	Hypoxia alters the synthesis and processing of collagens in human coronary artery smooth muscle cells	Sara M. Jørgensen, University of Copenhagen
P065	Immunology innovation program: Developing antibodies against novel targets through co-creation	Katrien Vanderheyden, Argenx
P066	The first AI-designed drug for idiopathic pulmonary fibrosis, rentosertib, reduces type III collagen in a human lung fibroblast scar-in-a-jar model	Frederik Højberg Svejsø, Nordic Bioscience
P067	Targeting type XI collagen to facilitate elimination of cancer-associated fibroblasts	Annika Hettich, Nordic Bioscience
P068	Innovative nanobody-based approaches to diagnose and treat collagen deposition in fibrotic disorders through PCPE1 targeting	Laura Chastagnier, Biologie Tissulaire et Ingénierie Thérapeutique

Nr.	Abstract Title	Presenter Author
P069	Targeting the ECM in HFpEF: Rationale and design of a phase 1c Proof-of-Mechanism trial of VS-041, a narrow-spectrum MMP Inhibitor	Noreen R. Henig, Vasa Therapeutics
P070	Targeting COL6A3-C5 with nigericin suppresses endotrophin formation and enhances insulin sensitivity in obesity	Chu-Sook Kim, UNIST
P071	Developing novel peritoneal drug delivery systems for prevention of post-operative adhesions	Elizaveta Miroshnik, University of Manchester
P072	Carbon dot nanotherapeutics modulating the polyol pathway and targeting infection pathogens associated with diabetic complications	Imane Nait Irahah, Hassan II University
P073	Highly selective inhibitors of Fibroblast Activation Protein (FAP) with prolonged residence times and promising radiotheranostic potential	Pieter Van Der Veken, University of Antwerp
P074	Improving the bioactivity of umbilical cord MSC-derived extracellular vesicles via priming strategies	Oksana Gorbatiuk, Institute of Molecular Biology and Genetics of NAS of Ukraine
P075	Hidradenitis suppurativa-derived fibroblasts display a pro-fibrotic phenotype relative to healthy control-derived fibroblasts	Helena Port, Nordic Bioscience
P076	Inhibition of Hedgehog signaling with Taladegib reduces fibrogenesis in a Scar-in-a-Jar model of pulmonary fibrosis	Mark Skarsfeldt, Nordic Bioscience
P077	The kaleidoscope of approaches to exploiting fibroblast activation protein in therapies for cancer and fibrosis	Mark Gorrell, Centenary Institute
P078	Inflammatory cytokines reshape the synovial fibroblast secretome and collagen formation during fibrotic stimulation in OA	Christian S. Thudium, Nordic Bioscience
P079	Integrin adapters control cell-matrix adhesion type	Elisa Burri, University of Geneva
P080	Fibrous ECM-mimetic scaffold for an immune-competent 3D human intestinal mucosa model of health and disease	Christina Naser, Fraunhofer
P081	Macrophage- and CD8 ⁺ T-cell-conditioned media drive fibrogenesis in a gastrointestinal Scar-in-a-Jar model; Upadacitinib suppresses immune-cell-mediated fibrogenesis, quantified by translational biomarkers	Thomai Tsapanou-Katranara, Nordic Bioscience
P082	Fibroblast activation protein (FAP)-cleaved type III collagen [C3F] is a potential marker for intestinal fibrosis in patients with Crohn's Disease	Thomai Tsapanou-Katranara, Nordic Bioscience
P083	Serological biomarkers of collagen formation and immune cell activity reflect fibrostenotic strictures in Patients with Crohn's disease – IBSEN-III study.	Joachim Hög Mortensen, Nordic Bioscience
P084	Collagen turnover and fibrogenesis biomarkers associate with kidney disease progression in CKD: Data from CRIC and NURTURE-CKD	Federica Genovese, Nordic Bioscience
P085	Survodutide, a novel dual GLP-1 receptor/glucagon receptor agonist, improves kidney health in a mouse model of advanced diabetic kidney disease	Henrik Björk Hansen, Gubra
P086	Dapagliflozin improves kidney function in the adenine-induced mouse model of chronic kidney disease	Maria Ougaard, Gubra
P087	The hemopexin domain of matrix metalloproteinase-9 attenuates lipopolysaccharide-induced interleukin-6 secretion in the liver	Yen-ting Chien, National Taiwan University
P088	Positron emission tomography imaging of liver fibrogenesis in MASH by targeting PDGFR-beta	Lars Johansson, Antares Tracer
P089	AI-derived macrophage density reveals hot and cold fibrosis endotypes with distinct biomarker profiles in metabolic dysfunction-associated steatohepatitis	Zoltan Derdak, Takeda
P090	A human-derived 3D ECM platform recapitulates clinically relevant matrix-driven pathophysiology in MASH fibrosis	Lisa Longato, Engitix Therapeutics
P091	Modelling metabolic dysfunction-associated steatohepatitis in human precision-cut liver slices	Christina Hesse, Fraunhofer

Nr.	Abstract Title	Presenter Author
P092	Integrin alpha 11 gene deletion ameliorates experimental sclerosing cholangitis	Richard Gilbert, University of Toronto
P093	Gated Distillation of miR networks uncovers DKK1 as a driver of MASLD-HCC and metastasis	Prakash Narayan, Nodes and Edges LLC
P094	Unsupervised biomarker clustering reveals clinically relevant subgroups in metabolic dysfunction-associated steatotic liver disease	Frederik Højbjerg Svejsø, Nordic Bioscience
P095	ADAPT and VCTE show comparable performance for identifying MASH patients with significant fibrosis: Implications for selecting patients eligible for therapy	Diana Julie Leeming, Nordic Bioscience
P096	Semaglutide improves metabolic and histological outcomes and reverses clinically relevant biomarker alterations in a diet-induced-obese mouse model of MASH	Line Zachariassen, Gubra
P097	The prognostic utility of the fibrosis non-invasive test panel FIB-NIT (PRO-C3, PRO-C6, CTX-III) in patients with alcohol-related liver disease	Andressa De Zawadzki, Nordic Bioscience
P098	The sequential use of LiverPRO and ADAPT enhances fibrosis detection in at-risk populations	Ida Lønsmann, Nordic Bioscience
P099	IN MATRICO® human liver fibrosis model reveals matrix-driven fibrotic cellular responses in 2D and 3D systems	Andrew Schmidt, Xylyx Bio
P100	Recapitulating liver ECM architecture via 3D Microprinting: A designed approach for enhanced in-vitro Liver models	Valeria Gonzalez Abrego, UCL
P101	The hemopexin domain of MMP-9 orchestrates depot-specific adipose tissue expansion by modulating lipid accumulation in visceral fat	Chien Huang, National Taiwan University
P102	Nintedanib lacks efficacy in a spirometry-confirmed and bleomycin-induced mouse model of idiopathic pulmonary fibrosis	Sarah Rank Rønnow, Gubra
P103	Targeting drug-induced tissue softening in fibrotic human lung slices	Ramaswamy Krishnan, Mechanobiologix
P104	Toward translationally aligned human 3d liver and lung fibrosis models: early biomarker-based validation	Helle Sedighi Frandsen, Celvivo
P105	Mapping profibrotic macrophage-ECM interactions across human precision-cut lung slices and IPF tissue	Safaa Naiel, European Molecular Biology Laboratory
P106	Biomarkers of tissue injury associate with lung function trajectories in COPD: a secondary analysis of the ECLIPSE cohort	Line Egerod, Nordic Bioscience
P107	Exploring fibrotic and inflammatory biomarkers for early detection of interstitial lung disease in rheumatoid arthritis: Secondary analysis of AURORA study	Rikke Malmkvist, Nordic Bioscience
P108	Early changes in serum PRO-C6 predict lung function trajectories in idiopathic pulmonary fibrosis	Jannie M. B. Sand, Nordic Bioscience
P109	Biomarkers of collagen turnover and immune cell activity distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis	Georgia Christoforidou, Nordic Bioscience
P110	AT2R agonists, C21 and NAc, inhibit IPF-like fibrogenesis in human precision cut lung slices	Olivia Young, Monash University
P111	Age- and smoke-related extracellular matrix alterations in human airways reveal early remodeling signatures linked to COPD development	Linda Elowsson, Lund University
P112	Beating lung-on-chip for modeling idiopathic pulmonary fibrosis and screening antifibrotic therapies	Roberta Visone, Biomimx
P113	Tankyrase inhibition demonstrates anti-fibrotic effects in preclinical pulmonary fibrosis models	Karl Martin Forbord, Oslo University Hospital
P114	The role of MUC5B misfolding in pulmonary fibrosis	Jessica Beasley, University of Leicester
P115	Markers of ECM remodeling and wound healing are associated with fibrostenotic Crohn's disease	Letizia Satriano, Nordic Bioscience

Nr.	Abstract Title	Presenter Author
P116	Human dermal fibroblast spheroids as a potential therapeutic modality	Hamid Khoja, Fibrobiologics
P117	Systemic proteomics of the PRIS cohort reveals calprotectin upregulation in periprosthetic joint infection	Sebastian L. Andree, Aalborg University
P118	Prevalence and mortality of extracellular matrix-related diseases	Rosa Colerick Christiansen, Nordic Bioscience
P119	In silico predicted tetra-peptides enhance human keratinocyte migration, proliferation and wound healing-related pathways	Alexander Eckersley, The University of Manchester
P120	Distal lung injury induces fibroblastic foci formation in terminal and respiratory bronchioles	Jeremy Herrera, University of Colorado Anschutz Medical Campus
P121	Fucosylation modulates phenotypic divergence in mature and tolerogenic human monocyte-derived dendritic cells	Misbah Khan, University of Galway
P122	Correlative and integrative bioinformatic analysis of public datasets reveals conserved changes in the basement membrane matrixome of ageing tissues	Krishna Pinganksha Purohit, University of Manchester
P123	A unique cysteine-type protein domain regulates cuticular extracellular matrix assembly in nematodes	Linxuan Li, MPI for Biology Tuebingen
P124	Decoding breast ECM responses to physiological status	Ellen Leonel, Uclouvain
P125	Age-related alterations in FAP- α activity in human skeletal muscle	Kirstine Mejlstrup Hymøller, Aarhus University
P126	Modulating extracellular matrix architecture through engineered dual-subunit peptide fragments	Mandana Mombeinipour, Tampere University
P127	Sodium valproate-induced remodeling of rat calcaneal tendons	Eli Heber Martins Dos Anjos, University of Campinas
P128	Mass spectrometry-based proteomics enables identification of natively cross-linked tryptic collagen peptides	Maximilian Maldacker, University Hospital Freiburg
P129	Investigating the role of PLOD2-Mediated lysine hydroxylation in collagen fibril stability and crosslink chemistry	Hannah Warren, University of Cambridge
P130	Dehydration stress drives functional collagen remodeling: molecular mechanisms and biological impact	Inna Solomonov, Weizmann Institute of Science
P131	Engineering biomimetic 3D collagen organisation in bone ECM under mechanical strain	Kathryn Gerl, University of Cambridge
P132	Identification of conserved extracellular matrix targets in fibrosis through cross-tissue proteomic analysis.	Jia Hua Wang, University of Cambridge
P133	MPLF2.0: A novel webtool for next-generation peptide location fingerprinting	Tess Birtles, University of Manchester
P134	A human ECM hydrogel platform reveals disease-specific matrixome drivers of fibrostenotic Crohn's Disease	Amy Lewis, Engitix Therapeutics
P135	Modeling healthy and impaired tendon healing: the roles of mechanical tension and inflammation	Alina Dintheer, University Hospital Balgrist
P136	An improved 3D hydrogel culture model to investigate the microenvironment of cancer progression	Amy Nyberg, University of Helsinki
P137	Endometriosis-in-a-Jar: a 12Z endometriotic epithelial cell model of extracellular matrix deposition is suppressed by the anti-inflammatory drug Budesonide.	Mark Skarsfeldt, Nordic Bioscience

Nr.	Abstract Title	Presenter Author
P138	Clinically validated markers of extracellular matrix remodeling are altered by anti-fibrotic compounds in a human skin ex vivo model	Cecilie Møller Hausgaard, Nordic Bioscience
P139	Improved study of fibrosis across tissues using immortalized cell line models	Elisabete Hernández, Innoprot
P140	Tunable synthetic hydrogel modulates hepatic lineage specification of human liver organoid	Yi-An Yang, Freie Universität Berlin
P141	Dissecting TGFβ-driven responses in fibroblasts using precision optogenetic in vitro systems	Benjamin McLean, Heinrich Heine Universität Düsseldorf
P142	Antifibrotic drug response in a long-term 3D human hepatic stellate cell model of progressive ECM Remodelling	Karoline Mikkelsen, Celvivo
P143	Fibroblasts in synthetic hydrogels: what do they teach us about disease progression and therapy resistance?	Maria Mitsi, University Hospital Zurich
P144	An ECM-based approach to enhancing mesenchymal stromal cell derivation from induced pluripotent stem cells	Thu Thuy Vu, The University of Sydney
P145	A single intraarticular injection of placental-expanded, mesenchymal-like stromal cells halts progression of experimental primary osteoarthritis	Tazio Maleitzke, University of Copenhagen
P146	Self-limiting versus persistent fibrosis: a cross-tissue single-nucleus atlas of musculoskeletal soft tissues	Yao Jiang, University of Oxford
P147	A medical device based on hyaluronic acid favors collagen deposition in cultured human tenocytes	Nicoletta Gagliano, University of Milan
P148	Extracellular matrix stiffness regulates muscle degeneration in Duchenne muscular dystrophy	Elisa Villalobos, University College London
P149	Inhibition of αv integrins with cilengitide reduces fibrosis and inflammation in the mdx-4cv mouse model of Duchenne muscular dystrophy	Enrique Brandan, Universidad San Sebastian
P150	Taking the Bait: using novel chemical probes to capture, visualize, and identify active serine proteases in osteoarthritic tissues	Mary Hines, University of Liverpool
P151	Collagen VI is a conserved pro-fibrotic signal disrupting muscle regeneration across distinct human myopathies	Laura Muraine, INSERM
P152	Dystrophin deficiency attenuates fibroadipogenic progenitor-mediated contractile maturation in 3D engineered muscle tissues	Hamed Ghazizadeh, Curi Bio
P153	Estrogen deficiency modulates postmenopausal osteoarthritis through reprogramming of the subchondral immunometabolism	Tazio Maleitzke, Charité-Universitätsmedizin Berlin
P154	The fibroblast activity biomarker, PRO-C11, is associated with disease activity and treatment response in patients with hidradenitis suppurativa	Signe Holm Nielsen, Nordic Bioscience
P155	Proteomic characterization of UV-induced skin remodeling and treatment response in an immunocompetent hairless mouse model	Martin Langeskov Bang, University of Copenhagen
P156	Type VII collagen degradation biomarker decreases after 12 weeks of abrocitinib and baricitinib in responding atopic dermatitis patients	Helena Port, Nordic Bioscience
P157	Characterization of skin calcium deposition, calcinosis cutis, in systemic sclerosis and dermatomyositis using ex vivo infrared spectroscopy	Laura Agerley Rørsgaard, Aarhus University Hospital
P158	Regulatory science-aligned development and pre-clinical evaluation of Lidocaine-embedded novel nanoemulgel for the management of Imiquimod-induced psoriasis in Balb/C mice	Ramesh Joga, NIPER Hyderabad
P159	Leveraging copper targeting to remodel the tumour microenvironment in pancreatic cancer	Ellie Mok, Garvan Institute Of Medical Research

Floor Plan



Exhibitors

1	Proteome Sciences	5	BiomimX	9	Incyte
2	Minerva Imaging	6	Gubra	10	Optics11 Life
3	MedChemExpress	7	AnaBios	11	Nordic Bioscience
4	Roche	8	Innoprot	12	Xylyx Bio

Sponsor & Exhibitor Directory

Roche Diagnostics



Founded in 1896 in Basel, Switzerland, Roche has grown into the world's largest biotechnology company and a global leader in in-vitro diagnostics. The company is dedicated to scientific excellence, discovering and developing medicines and diagnostics to improve and save lives. A pioneer in personalized healthcare, Roche aims to transform healthcare delivery by partnering with many stakeholders, combining strengths in Diagnostics and Pharma with clinical data insights. For more information, please visit:

www.roche.com

Nordic Bioscience



Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

www.nordicbioscience.com

AnaBios



Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, pain and itch. In addition to working with Fortune 500 biotech companies, CROs and academia, AnaBios drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry.

www.anabios.com

AstraZeneca



AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

www.astrazeneca.com

Bristol Myers Squibb



Bristol Myers
Squibb™

Vision: To be the world's leading biopharma company that transforms patients' lives through science.

Mission: To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Tagline: Transforming Patients' Lives Through Science.

Values: Integrity, Urgency, Accountability, Innovation, Passion, Inclusion.

www.bms.com

Sponsor & Exhibitor Directory

FibroBiologics



FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of fibroblast-based therapeutics for diabetic foot ulcers (DFUs), multiple sclerosis, degenerative disc disease (DDD), psoriasis, joint cartilage repair, thymus based immune system revitalization for human longevity, and cancer.

www.fibrobiologics.com

FibroFind



FibroFind is a UK-based biotechnology company transforming preclinical research through human precision-cut tissue slice platforms. Our patented bioreactor preserves the viability and function of human liver, lung, kidney, heart, and skin tissue, generating data that mirror true human biology. Trusted globally by leading pharmaceutical and biotech partners, FibroFind delivers confident, risk-reducing insights that enhance decision-making and accelerate discovery with unmatched scientific precision and translational relevance.

www.fibrofind.com

Incyte



Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity. Our research and development efforts in Dermatology are focused on leveraging our cross-program knowledge to explore the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, and hidradenitis suppurativa.

www.incyte.com

Takeda



The GI2 TAU Early Development & Biomarkers (EDB) organization accelerates innovative therapies. EDB integrates Early Clinical Development, Early Phase Global Program Leads, Biomarker Leadership, and Computational Biology & Digital to drive datadriven decisionmaking across programs. With dedicated teams in inflammation and fibrosis biology, clinical execution, and translational science, EDB strengthens crossfunctional alignment, enhances scientific rigor, and ensures efficient progression of GI2's earlyphase portfolio.

www.takeda.com

Xylyx Bio



Xylyx Bio specializes in the development, manufacturing, and commercialization of tissue-derived decellularized extracellular matrix (dECM) kits and assays for human disease modeling and drug testing. Leveraging its InMatrico® platform and TissueSpec® dECM product line, Xylyx Bio translates advances in extracellular matrix biology into standardized, scalable research tools. These products enable scientists to incorporate tissue-specific dECM into in-vitro models, enhancing physiological relevance and improving disease modeling fidelity. By more accurately recapitulating human tissue specific extracellular microenvironments, Xylyx Bio is helping to bridge the gap between conventional laboratory models and human biology.

www.xylyxbio.com

AbbVie



AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and through our Allergan Aesthetics portfolio.

www.abbvie.com

Engitix Therapeutics



Engitix is transforming drug discovery by harnessing the power of the extracellular matrix (ECM) to develop breakthrough therapies for fibrosis, inflammation, and solid tumors. Its proprietary, end-to-end discovery platform integrates human-derived ECM scaffolds with advanced computational and AI/ML tools, creating predictive 3D systems that mirror human biology and de-risk development. Supported by strong partnerships and validated science, Engitix is redefining how complex diseases are understood, modeled, and treated.

www.engitix.com

GSK - GlaxoSmithKline



As a focused biopharma company, GSK discovers, develops and delivers medicines and vaccines to create value for patients and shareholders. GSK aims to positively impact the health of 2.5 billion people by the end of the decade. GSK's R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

www.gsk.com

Gubra



Gubra is a disease-agnostic company specializing in peptide-based drug discovery and preclinical contract research services. Operating through three synergistic business units, Biotech, CRO, and Ventures, we combine scientific excellence with strong value creation and a firm commitment to society. Our team of 300+ employees collaborates with industry and academia to improve the quality of people's lives.

www.gubra.dk

Insilico Medicine



Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products, and veterinary medicine.

www.insilico.com

Inventiva



Inventiva is a late-stage clinical biopharmaceutical company focused on the development of oral therapies for patients with significant unmet medical needs. The Company is advancing efforts to develop a potential oral treatment targeting metabolic dysfunction-associated steatohepatitis (MASH), a progressive disease affecting both the liver and multiple systemic metabolic pathways.

www.inventivapharma.com

Sponsor & Exhibitor Directory

Mediar Therapeutics



Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar's exploratory medicines aim to disable the myofibroblast, slow fibrosis, and enable healing. Mediar is conducting Phase 2 clinical studies to bring new potential options for patients and their caregivers.

www.mediartx.com

Novo Nordisk



Novo Nordisk is a global healthcare company headquartered in Denmark, focused on driving change to defeat serious chronic diseases. With a strong heritage in diabetes care, the company is a leader in treatments for diabetes, obesity, and rare endocrine disorders. Novo Nordisk combines scientific innovation with a commitment to improving patient outcomes and expanding access to care worldwide.

www.novonordisk.com

Optics11 Life



At Optics11 Life we develop a suite of mechanobiology tools, including high-precision, high-throughput instruments for cell-to-tissue nanoindentation, and a non-destructive contractility platform that monitors 3D muscle-bundle dynamics. Together, these instruments quantify stiffness, viscoelasticity, and force generation under near-physiological conditions, giving researchers fast, actionable data for advanced disease modelling, drug screening and biomaterial quality control. Our products are used across diverse application areas, including fibrosis, oncology, cardiology, muscle diseases, and regenerative medicine.

www.optics11life.com

PharmaNest



PharmaNest is an AI-enabled Digital Pathology focused on the development and validation of novel standards for the quantification of the histological phenotype(s) of Fibrosis and associated histological features. PharmaNest accelerates the discovery and development of novel anti-fibrotic therapies and related diagnostics. For more information about FibroNest and PharmaNest, visit:

www.pharmanest.com

Tribune Therapeutics



Tribune Therapeutics is a Nordic biotech company pioneering therapies for fibrotic diseases through deep expertise in CCN biology. Its lead candidate, TRX-44, a human albumin fusion protein, targets key pro-fibrotic CCN signaling pathways to halt fibrosis progression and preserve lung function in idiopathic pulmonary fibrosis. Tribune combines cutting-edge science and strategic collaborations to deliver transformative treatments for patients worldwide.

www.tribunetx.com

Zealand Pharma



Zealand Pharma is a biotechnology company advancing medicines for obesity and metabolic health. Combining nearly 30 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Denmark, with an office in Boston.

www.zealandpharma.com

BiomimX



BiomimX® develops advanced human organs-on-chip integrating tunable mechanical stimulation to recreate physiological and pathological conditions. With proprietary uBeat® technology, we provide predictive 3D in vitro models of heart, gut, lung, joint and fibrosis, supporting drug discovery, safety assessment and efficacy studies through both product and service offerings.

www.biomimx.com

Innoprot



Innoprot provides advanced cell-based assays, as well as primary, immortalised and recombinant cell lines, for drug discovery. We develop in vitro systems that enable the study of fibrosis and extracellular matrix remodelling, facilitating phenotypic and high-content analysis for compound screening and the quantification of key biomarkers.

www.innoprot.com

Johnson & Johnson



At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

www.jnj.com

MedChemExpress



MedChemExpress (MCE), a premier global supplier, offers 100,000+ inhibitors & agonists targeting 20+ key pathways. We support drug discovery with our all-in-one platform, custom synthesis (ADCs, PROTACs), and specialized libraries, empowering your research with innovative tools and solutions.

www.medchemexpress.com

Minerva Imaging



Founded in 2011, Minerva Imaging is a CRO/CDMO with deep expertise in molecular and preclinical imaging. We specialize in longitudinal assessment of fibrosis, inflammation, and tissue remodeling across organ systems and disease models, combining echocardiography, MRI, CT, SPECT, and PET to generate clinically aligned, translational datasets.

www.minervaimaging.com

Sponsor & Exhibitor Directory

Merck & Co.



At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

www.msd.com

Pfizer



Breakthroughs That Change Patients' Lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

www.pfizer.com

Proteome Sciences



We are a CRO specialising in the analysis of proteins and their associated PTM's via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.

www.proteomics.com

IN MATRICO®

*Tissue-Specific Decellularized Extracellular Matrix (dECM) —
the platform behind your next disease model*

IN MATRICO® ("in matrix") is the only platform offering a structured portfolio of tissue-specific dECMs across multiple tissues.

- 01 EXPERTISE**
Growing library of characterized and validated dECMs from a range of tissues
- 02 INNOVATION**
Proprietary decellularization preserves native ECM composition and bioactivity
- 03 IMPACT**
Accelerates disease modeling by recreating tissue microenvironments

info@xylyxbio.com | +1 (212) 689-9005 | www.xylyxbio.com/in-matrico/

XYLYX



7

TISSUES

2

SPECIES

3

FORMATS

VISIT OUR BOOTH

Media Partners

American Society for Matrix Biology



The American Society for Matrix Biology (ASMB) promotes basic, translational, and clinical research on the extracellular matrix (ECM), cell-ECM interactions, and ECM-based therapies and devices. It supports professional growth and collaboration among academia, industry, government, and scientific societies through knowledge dissemination, mentoring, and advocacy for sustained research funding. ASMB membership offers networking, meeting and journal discounts, and award opportunities for ECM scientists.

www.asmb.net

British Society for Matrix Biology



The British Society for Matrix Biology (BSMB) brings together scientists interested in the ECM to provide a forum for exchanging ideas and promoting ECM research and education. It organizes meetings for researchers from the UK and beyond and supports younger scientists through bursaries and awards, while also advancing public education about matrix biology.

www.bsmb.ac.uk

Danish Biochemical Society



The Danish Biochemical Society supports life science research and scientific exchange in Denmark with particular emphasis on biochemistry and molecular biology. It facilitates collaboration among researchers through meetings, symposia, and networking opportunities. As an umbrella organization for life science societies (including the Danish Society for Matrix Biology), it helps connect specialists across disciplines and promotes the development and dissemination of biochemical research nationally.

www.biokemi.eu

Danish Society for Matrix Biology



The Danish Society for Matrix Biology (DSMB) is a network for advancing connective tissue and ECM biology research in Denmark. It arranges seminars, lectures, discussion groups, conferences, symposia, and networking events for scientists in the field, and is affiliated with the Danish Biochemical Society.

www.dsmb.dk

Dutch Society for Matrix Biology



The Nederlandse Vereniging voor Matrix Biologie (NVMB) promotes scientific research into both fundamental and applied aspects of the ECM in health and disease. It unites matrix biology researchers from Dutch universities and research institutes, offering a forum for exchange and networking. NVMB's annual two-day meeting focuses on scientific presentations and discussion, with special opportunities for PhD students to present their work and build connections. NVMB also awards prizes, such as the Pauline van Wachem and Bertus Kemp prizes, to recognize outstanding contributions in the field.

www.matrixbiology.nl

Finnish Society for Matrix Biology



The Finnish Society for Matrix Biology (Sidekudostutkijat ry) aims to promote and support research into connective tissues and ECM biology in Finland. It encourages cooperation among its members and the dissemination of the latest scientific knowledge relevant to the field. The society organizes annual meetings and participates in regional matrix biology activities, including collaborations with other societies. As part of the Federation of Finnish Learned Societies, it helps connect ECM researchers to a broader academic network.

www.sidekudostutkijat.fi

Media Partners

French Society for Matrix Biology



The French Society for Matrix Biology (SFBMEc) promotes research and knowledge exchange on ECM biology across diverse scientific and medical disciplines. It organizes annual meetings that bring together researchers and clinicians to discuss ECM dynamics in physiology and disease and supports activities such as conference travel grants for students and postdocs.

www.sfbmec.fr

German Society for Matrix Biology



The German Society for Matrix Biology (DGMB) supports research aimed at understanding the ECM and its role in connective tissue biology and disease. The society facilitates scientific exchange by organizing annual meetings, encourages interdisciplinary interaction between researchers and clinicians, and supports young scientists through awards and travel grants.

www.matrixbiologie.de

Hellenic Society for Biochemistry and Molecular Biology



The Hellenic Society for Biochemistry and Molecular Biology (HSBMB) aims to promote research and exchange in biochemistry, molecular biology, and related fields. HSBMB is highly active in the field of ECM research, and for this purpose the Hellenic Matrix Biology Section of HSBMB has been established, bringing together researchers working on ECM biology, pathology, and therapeutic targeting.

www.eebmb.gr/index.php/en/groups

International Society for Matrix Biology



The International Society for Matrix Biology (ISMB) fosters global scientific exchange on ECM research and supports professional development of young scientists. It organizes and sponsors ECM workshops and scientific meetings, disseminates information on techniques and publications, and recognizes excellence with awards like the Rupert Timpl and Distinguished Investigator awards. Membership benefits include travel awards, reduced conference fees, and access to society resources.

www.ismb.org

Keystone Symposia



Keystone Symposia is a nonprofit organization headquartered in Silverthorne, Colorado, USA that advances biomedical and life sciences by connecting researchers through conferences and workshops worldwide. Its meetings bring together academic, industry, and global health experts to encourage collaboration, innovation, and translational research with medical impact. The organization also supports the next generation of scientists through scholarships, travel awards, networking, and career-development opportunities for students, postdoctoral fellows, and early-career researchers.

www.keystonesymposia.org

Kidney Week



Kidney Week, organized by the American Society of Nephrology (ASN), is the world's premier nephrology meeting, bringing together more than 12,000 kidney professionals from around the globe. The conference provides opportunities to exchange knowledge, explore the latest scientific and medical advances, and engage in discussions with leading experts in kidney research and patient care. Kidney Week features scientific sessions, abstract presentations, networking opportunities, and educational programs that support innovation and collaboration across the nephrology community.

www.asn-online.org/education/kidneyweek

**Matrix Biology
Society
of Australia and
New Zealand**



The Matrix Biology Society of Australia and New Zealand (MBSANZ) brings together researchers, clinicians, and industry leaders with interest in ECM biology, focusing on its roles in development, maintenance, pathology, and repair of tissues. MBSANZ fosters collegiate discussion, knowledge transfer, networking, and recognition of outstanding research via awards for members at different career stages.

www.mbsanz.org

**STEMCELL
Science News**



STEMCELL Science News is a complete resource for the latest cell biology news and research, from organoids to immunology. With a curated selection of high-impact publications, reviews, jobs, events, and news, STEMCELL Science News features research updates across a website, X feeds, and 20 email newsletters. Extracellular Matrix News by STEMCELL Technologies Science News keeps scientists updated on the latest extracellular matrix research. Subscribe for free: www.stemcellsciencenews.com/extracellular-matrix-news.

www.stemcellsciencenews.com

**World Congress
on Osteoporosis,
Osteoarthritis and
Musculoskeletal
Diseases**



The WCO-IOF-ESCEO Congress is a leading international conference focused on osteoporosis, osteoarthritis, and musculoskeletal diseases. Organized by the International Osteoporosis Foundation (IOF) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), the event brings together global experts, clinicians, and researchers to share the latest advances in bone, joint, and muscle health. The congress features scientific sessions, abstract presentations, and networking opportunities that support innovation in prevention, diagnosis, and treatment.

www.wco-iof-esceo.org

Notes

NORDIC PROTEINFINGERPRINT TECHNOLOGY™

The ECM biomarker powerhouse. No biopsy needed.

Quantify tissue remodeling across fibrotic, inflammatory, metabolic and oncology indications, from a single blood sample.

30+ years ECM research · 850+ publications · CAP / CLIA accredited lab

SELECTED BIOMARKERS

PRO-C3

PRO-C6

CPa9-HNE


SELECTED PANELS

FIB-NIT™

RheumaTrace™



Follow us
on LinkedIn



NORDIC BIOSCIENCE

bd@nordicbioscience.com

+45 4452 5252

nordicbioscience.com

Thank you to our sponsors and exhibitors

Gold Sponsors



Silver Sponsors



Bronze Sponsors



Exhibitors

